Comparative Pharmacology
Head-to-head clinical analysis: CUPRIMINE versus DEPEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CUPRIMINE versus DEPEN.
CUPRIMINE vs DEPEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Chelates copper, forming a stable complex that is excreted renally, reducing systemic copper accumulation.
Penicillamine is a chelating agent that forms soluble complexes with heavy metals (e.g., copper, mercury, lead) and promotes their renal excretion. In rheumatoid arthritis, it reduces rheumatoid factor and immune complexes, and inhibits collagen cross-linking.
250-500 mg orally 4 times daily, titrated to maintain urinary copper excretion >2 mg/day. Maximum: 2 g/day.
250 mg orally 4 times daily, target dose 1000-1500 mg/day in divided doses.
None Documented
None Documented
Terminal half-life: 4–6 hours. Clinical context: After discontinuation, urinary copper excretion declines within 2–3 hours but may persist for several days due to tissue redistribution.
1.5-4 hours; prolonged to 6-12 hours in renal impairment; clinical context: dosing interval adjustments needed in CKD.
Renal: ~80% as unchanged drug, biliary/fecal: <5%
Renal: 50% as unchanged drug; biliary/fecal: minor, <5%.
Category C
Category C
Chelating Agent
Chelating Agent